Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study

2013 ◽  
Vol 43 (1) ◽  
pp. 48-54 ◽  
Author(s):  
Aharna Guin ◽  
Maitrayee Chatterjee Adhikari ◽  
Sumit Chakraborty ◽  
Pradyot Sinhamahapatra ◽  
Alakendu Ghosh
Rheumatology ◽  
2000 ◽  
Vol 39 (9) ◽  
pp. 1009-1013 ◽  
Author(s):  
S. Aman ◽  
L. Paimela ◽  
M. Leirisalo-Repo ◽  
J. Risteli ◽  
H. Kautiainen ◽  
...  

2012 ◽  
Vol 79 (1) ◽  
pp. 43-46 ◽  
Author(s):  
Karima Benbouazza ◽  
Hanan Rkain ◽  
Bahia Benchekroun ◽  
Bouchra Amine ◽  
Fatiha Bzami ◽  
...  

1998 ◽  
Vol 8 (2) ◽  
pp. 117-129
Author(s):  
Kenichi Miyagi ◽  
Takeshi Azuma ◽  
Akifumi Naitoh ◽  
Hiroyuki Sakaida ◽  
Moromichi Sakata ◽  
...  

2011 ◽  
Vol 71 (3) ◽  
pp. 374-377 ◽  
Author(s):  
Katerina Chatzidionysiou ◽  
Elisabeth Lie ◽  
Evgeny Nasonov ◽  
Galina Lukina ◽  
Merete Lund Hetland ◽  
...  

ObjectivesTo compare the effectiveness and safety of rituximab alone or in combination with either methotrexate or leflunomide.Methods10 European registries submitted anonymised datasets with baseline, 3, 6, 9 and 12-month clinical data from patients who started rituximab.Results1195 patients were treated with rituximab plus methotrexate, 177 with rituximab plus leflunomide and 505 with rituximab alone. Significantly more patients achieved a European League Against Rheumatism good response at 6 months when treated with rituximab plus leflunomide (29.1%) compared with rituximab plus methotrexate (21.1%) and rituximab alone (19.3%; p=0.02 and p=0.01, respectively). Similar results were observed at 12 months. Adverse events occurred in 10.2%, 13.2% and 13.9% of patients on rituximab plus leflunomide, rituximab plus methotrexate and rituximab alone, respectively.ConclusionsLeflunomide is an effective and safe alternative to methotrexate as concomitant treatment with rituximab. Slightly better results were obtained by the combination of rituximab and leflunomide than rituximab and methotrexate, raising the possibility of a synergistic effect of leflunomide and rituximab.


2011 ◽  
Vol 12 (1) ◽  
Author(s):  
Karima Benbouazza ◽  
Bahia Benchekroun ◽  
Hanan Rkain ◽  
Bouchra Amine ◽  
Fatiha Bzami ◽  
...  

1998 ◽  
Vol 8 (2) ◽  
pp. 117-129
Author(s):  
Kenichi Miyagi ◽  
Takeshi Azuma ◽  
Akifumi Naitoh ◽  
Hiroyuki Sakaida ◽  
Moromichi Sakata ◽  
...  

Rheumatology ◽  
1992 ◽  
Vol 31 (8) ◽  
pp. 519-525 ◽  
Author(s):  
D. M. F. M. VAN DER HEIJDE ◽  
P. L. C. M. VAN RIEL ◽  
M. A. VAN LEEUWEN ◽  
M. A. VAN'T HOF ◽  
M. H. VAN RIJSWIJK ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document